Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm 4-year study of Ocrevus in progressive multiple sclerosis
2023-506429-13-00Phase 3Completed
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoints: Proportion of patients with no evidence of progression sustained for at least 24 weeks and Proportion of patients with NEPAD sustained for at least 24 weeks. Started May 2018; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-506429-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506429-13-00.